2-Methyl-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine → 6-(3-(Hydroxymethyl)azetidin-1-yl)-5-(2-methylpyrimidin-5-yl)-N-(4-(trifluoromethoxy)phenyl)nicotinamide

HRID 923970Notes

Reaction equation

HRID 923970 reaction equation
Br[C:2]1[C:3]([N:22]2[CH2:25][CH:24]([CH2:26][OH:27])[CH2:23]2)=[N:4][CH:5]=[C:6]([CH:21]=1)[C:7]([NH:9][C:10]1[CH:15]=[CH:14][C:13]([O:16][C:17]([F:20])([F:19])[F:18])=[CH:12][CH:11]=1)=[O:8].[CH3:28][C:29]1[N:34]=[CH:33][C:32](B2OC(C)(C)C(C)(C)O2)=[CH:31][N:30]=1>>[OH:27][CH2:26][CH:24]1[CH2:25][N:22]([C:3]2[C:2]([C:32]3[CH:31]=[N:30][C:29]([CH3:28])=[N:34][CH:33]=3)=[CH:21][C:6]([C:7]([NH:9][C:10]3[CH:15]=[CH:14][C:13]([O:16][C:17]([F:20])([F:19])[F:18])=[CH:12][CH:11]=3)=[O:8])=[CH:5][N:4]=2)[CH2:23]1

Participants

3

Procedure

The title compound was prepared in an analogous fashion to that described in Example 128 using 5-bromo-6-(3-(hydroxymethyl)azetidin-1-yl)-N-(4-(trifluoromethoxy)phenyl)nicotinamide (Stage 135.1) and 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine. HPLC (Condition 4) tR=4.61 min, UPLC-MS (Condition 3) tR=0.95 min, m/z=460.3 [M+H]+; 1H-NMR (400 MHz, DMSO-d6) δ ppm 2.55-2.63 (m, 1H) 2.67 (s, 3H) 3.39-3.52 (m, 4H) 3.73 (t, J=8.60 Hz, 2H) 4.69 (t, J=5.28 Hz, 1H) 7.34 (d, J=8.99 Hz, 2H) 7.79-7.88 (m, 2H) 8.01 (d, J=2.35 Hz, 1H) 8.70-8.82 (m, 3H) 10.18 (s, 1H).

Sources & evidence

ORD record
ord-8ee17ca081144dd8afa3c275560fdae2
Source dataset
uspto-grants-2016_03
Patent number
US09278981B2

Reaction notes

Loading…